Stockreport

Bioverativ Announces FDA Acceptance of Investigational New Drug Application for BIVV001 to Treat Hemophilia A

BIOVERATIV INC COMMON  (BIVV) 
Last bioverativ inc common earnings: 2/13 04:15 pm Check Earnings Report
PDF BIVV001 is a novel, investigational factor VIII therapy designed to extend protection from bleeds with prophylaxis dosing of once weekly or l [Read more]